A novel dual-mode biosensor integrating surface-enhanced Raman spectroscopy (SERS) and electrochemiluminescence (ECL) was developed for the reliable detection of acute myocardial infarction (AMI) related circulating miRNAs. The DNA walker nucleic acid amplification technique was employed for signal amplification and facilitated in-situ synthesis of ECL luminescent clusters and SERS probes. The alkynyl-modified silver nanocluster (AgNC) template strand and the azido-modified DNA probe on the electrode were connected through linker release facilitated by the continuous rolling and cutting action of the DNA walker on the spherical substrate. Under Cu catalysis, the alkynyl and azide groups at the junction undergo conversion into triazole molecules, which can serve as SERS probes. Subsequently, AgNCs were synthesized using a template method, with SERS signals emitted due to plasma resonance effects of triazole molecules situated between Au nanoparticles and AgNCs. The developed dual-mode analysis platform efficiently minimizes the potential for signal leakage, significantly corrects systematic errors, improves detection accuracy and sensitivity, and facilitates dependable identification of circulating miRNA. The detection of miRNA-133a exhibited a linear relationship within the concentration range of 100 aM to 1 nM, with detection limits of 32 aM and 0.17 fM in ECL and SERS modes, respectively. The SERS-ECL dual-mode detection platform may provide forward-looking ideas for the field of biosensing and clinical analysis.

中文翻译：

---

双模式 SERS-ECL 生物传感器，用于基于原位合成探针的循环 miRNA 的稳健检测


开发了一种集成表面增强拉曼光谱 (SERS) 和电化学发光 (ECL) 的新型双模式生物传感器，用于可靠检测急性心肌梗死 (AMI) 相关的循环 miRNA。采用DNA walker核酸扩增技术进行信号放大，促进ECL发光簇和SERS探针的原位合成。炔基修饰的银纳米簇 (AgNC) 模板链和电极上的叠氮基修饰的 DNA 探针通过 DNA 行走器在球形基底上的连续滚动和切割作用促进的接头释放来连接。在 Cu 催化下，连接处的炔基和叠氮基团转化为三唑分子，可用作 SERS 探针。随后，使用模板法合成了 AgNC，由于位于 Au 纳米粒子和 AgNC 之间的三唑分子的等离子体共振效应，发出 SERS 信号。开发的双模式分析平台有效地最大限度地减少了信号泄漏的可能性，显着纠正了系统错误，提高了检测准确性和灵敏度，并促进了循环 miRNA 的可靠识别。 miRNA-133a 的检测在 100 aM 至 1 nM 的浓度范围内呈现线性关系，ECL 和 SERS 模式下的检测限分别为 32 aM 和 0.17 fM。 SERS-ECL双模式检测平台可能为生物传感和临床分析领域提供前瞻性的思路。